Genomic testing and therapies for breast cancer in clinical practice

American Journal of Managed Care

Volumn 17, Issue 5, 2011, Pages

  Haas, Jennifer S ^a   Phillips, Kathryn A ^a   Liang, Su Ying ^a   Hassett, Michael J ^a   Keohane, Carol ^a   Elkin, Elena B ^a   Armstrong, Joanne ^a   Toscano, Michele ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL PRACTICE; FEMALE; GENE EXPRESSION PROFILING; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; GENES, ERBB-2; GENETIC TESTING; HUMANS; MEDICAL AUDIT; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PRIMARY HEALTH CARE;

EID: 79960205965     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Phillips KA: Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 300:2542-2544, 2008
2. Barron JJ, Cziraky MJ, Weisman T, et al: HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 14:760-768, 2009
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005 (Pubitemid 41464706)
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005 (Pubitemid 41464705)
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006 (Pubitemid 43290919)
7. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
8. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
9. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
10. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer v. 1.2009. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp
11. Kolata G: Cancer fight: unclear tests for new drug. New York Times, April 20, 2010:A1
12. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
13. Renshaw RN: Outcomes-based access: what will it mean for biologics? Biotechnol Healthc 39-44, 2006
14. Hillner BE, Smith TJ: Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 25:611-613, 2007
15. Barrett A, Roques T, Small M, et al: How much will Herceptin really cost? BMJ 333:1118-1120, 2006
16. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004 (Pubitemid 40051905)
17. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
18. Albain K, Barlow W, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
19. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006 (Pubitemid 46622311)
20. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
21. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006 (Pubitemid 44288785)
22. Aetna: Clinical policy bulletin number 352: Tumor markers. Aetna, Hartford, CT, 2009
23. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000 (Pubitemid 32007842)
24. Nielsen Claritas Update Demographics Methodology. Nielson Company, New York, NY, 2009
25. Phillips KA, Marshall DA, Haas JS, et al: Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 115:5166-5174, 2009
26. Coulson SG, Kumar VS, Manifold IM, et al: Review of testing and use of adjuvant trastuzumab across a cancer network: Are we treating the right patients? Clin Oncol (R Coll Radiol) 22:289-293, 2010
27. Stark A, Kucera G, Lu M, et al: Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care 16:517-521, 2004 (Pubitemid 39625161)
28. Bickell NA, LePar F, Wang JJ, et al: Lost opportunities: Physicians' reasons and disparities in breast cancer treatment. J Clin Oncol 25:2516-2521, 2007 (Pubitemid 47041223)
29. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002 (Pubitemid 34705057)
30. Bartlett JM: Pharmacodiagnostic testing in breast cancer: Focus on HER2 and trastuzumab therapy. Am J Pharmacogenomics 5:303-315, 2005
31. Newcomer LN: Insurers and 'targeted biologics' for cancer: A conversation with Lee N. Newcomer-Interview by Barbara J. Culliton. Health Aff (Millwood) 27:w41-w51, 2008
32. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007 (Pubitemid 46435378)
33. Gold JM, Najita JS, Lester S, et al: Personalizing treatment in early-stage breast cancer: the role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 29-June 2, 2009
34. Oestreicher N, Ramsey SD, Linden HM, et al: Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 7:380-389, 2005
35. Krieger N, Chen JT, Waterman PD, et al: Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health 95:312-323, 2005 (Pubitemid 40179832)
36. Tong KB, Chen E, Kim GD: HER2 testing and trastuzumab use in the Medicare population. Presented at the 2007 Breast Cancer Symposium, San Francisco, CA, September 7-8, 2007